.png)
.png)
.jpg "Olga Lomovskaya, PhD photo")
Senior Vice President
Qpex Biopharma
Disclosure(s): No financial relationships to disclose
Dr. Lomovskaya is a Founder and Senior Vice-President of Discovery and Clinical Microbiology at Qpex Biopharma with 25 years of experience in anti-microbial drug discovery and development and is an expert in the field of antimicrobial resistance.
Her industrial career started in 1995 at Microcide Pharmaceuticals where she pioneered the field of microbial multi-drug resistant efflux pumps and various approaches to overcome efflux-mediated resistance. From 2003 to 2011 she was with Mpex Pharmaceuticals as a Director and later, Vice-President of Biology, supporting pre-clinical development and MAA approval of Quinsair, an inhaled formulation of levofloxacin for Cystic Fibrosis. In 2011 she became one of the founders of Rempex Pharmaceuticals (acquired by The Medicines Company in 2013) and led the efforts to discover novel beta-lactamase inhibitors and provide biology support for the development of beta-lactam/beta-lactamase inhibitors combinations resulting in NDA/MAA approval of Vabomere (meropenem-vaborbactam).
She received her Ph.D. in molecular genetics from the Institute of Molecular Genetics, Russian Academy of Sciences and her M.S. in molecular biology from Moscow State University, with research appointments at MIT, Cal Tech and Stanford.
Dr. Lomovskaya is an inventor on over 20 patents and patent applications, authored over 50 original papers, review articles and book chapters and is serving as a member of editorial boards of several scientific journals including Antimicrobial Agents and Chemotherapy and Journal of Bacteriology. She is a frequent speaker at National and International Conferences and in 2009 served as Chair of Gordon Conference on Multidrug Resistance. In 2018 Dr. Lomovskaya was elected as a fellow of American Academy of Microbiology.